1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response (Others) -  AVAILABLE ON REQUEST BY EMAIL TO: Indiperstudy@gmail.com


6. For how long will this data be available start date provided 01-10-2022 and end date provided 30-09-2027?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Pulmonary thromboembolism (PE) is a well-known fatal disease, especially in the first month of its presentation. It is estimated that the annual incidence of pulmonary thromboembolism ranges from 20.8 to 210 per 100000 and its short-term mortality ranges from less than 1% to more than 30% during the hospital stay. In USA, approximately 10 % of patients die within 1 hour after a PE. There is very limited data from India, that too from retrospective or single center studies.

Pulmonary thromboembolism has a variable and frequently nonspecific clinical presentation, which is a diagnostic challenge with the risk of underestimating its real incidence and delaying the initiation of specific treatment that will result in a worse prognosis. This situation indicates that PE is one of the main cause of preventable in-hospital mortality. Diagnosis starts with clinical probability assessment mainly based on medical history and rapidly available clinical data. Recent guidelines recommend to tailor diagnosis, hospitalization and acute treatment based on the estimated risk for short-term death.

Pulmonary thromboembolism can be managed by pulmonology, cardiology, emergency, critical care or internal medicine physicians. Thus, initial clinical management can varies based on the attitude of the attending physician.

Although there are numerous international registries that have collaborated in defining risk factors and their natural history, there is scanty information in India about the presentation and management of PE. Thus, despite the advances and growing interest in this disease, there are still large “grey areas” and controversies, especially with regard to treatment in its acute phase.

The observational study that aims to assess the clinical profiles of the diagnosis and treatment strategies is the one that best portrays the reality of clinical practice. With this type of evaluation results will not be subject to interferences generated in controlled studies, with close surveillance of the patients included.